Glucagon in MODY
Research type
Research Study
Full title
Investigating glucagon secretion in HNF1-alpha and HNF4-alpha MODY
IRAS ID
221972
Contact name
Ioannis Spiliotis
Contact email
Sponsor organisation
University of Oxford
Clinicaltrials.gov Identifier
2016-005254-38, EudraCT
Duration of Study in the UK
0 years, 6 months, 1 days
Research summary
Diabetes is a chronic condition that affects 1 in 16 people in the UK, and leads to difficulty controlling blood sugar levels. This is due to an imbalance between two main hormones: insulin, which lowers blood sugar, and glucagon, which causes it to rise. Most patients have type 2 diabetes and are managed on a number of different medications including a new class called SGLT-2 inhibitors. MODY (Maturity Onset Diabetes of the Young) is a form of diabetes due to specific gene mutations and affects a much smaller group of patients. However, they are usually managed very well on one specific class of medication called sulphonylureas. Recent studies have suggested a link between MODY and the way SGLT-2 inhibitors work. The aim of this study is to better understand the role of glucagon in MODY patients, as this may point towards an improved treatment strategy of using SGLT-2 inhibitors along with low doses of sulphonylureas in type 2 diabetes.
REC name
South Central - Hampshire B Research Ethics Committee
REC reference
17/SC/0233
Date of REC Opinion
5 May 2017
REC opinion
Favourable Opinion